NASDAQ: ATYRAtyr Pharma Inc Stock Ownership - Who owns Atyr Pharma?
Insider buying vs selling
Have Atyr Pharma Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Paul Schimmel | Director | 2026-05-27 | 100,000 | $0.50 | $49.60kBuy |
| Jill Marie Broadfoot | Chief Financial Officer | 2026-02-04 | 1,558 | $0.98 | $1.52kSell |
| Nancy Denyes | General Counsel | 2026-02-04 | 1,118 | $0.98 | $1.09kSell |
| Sanjay Shukla | President and CEO | 2026-02-04 | 3,745 | $0.98 | $3.66kSell |
ATYR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when ATYR insiders and whales buy or sell their stock.
ATYR Shareholders
What type of owners hold Atyr Pharma Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Srinivas Akkaraju | 1.90% | 1,866,126 | $238.86k | Insider |
| Sofinnova Venture Partners IX LP | 1.90% | 1,866,126 | $238.86k | Insider |
| Amir Nashat | 1.88% | 1,840,564 | $235.59k | Insider |
| Polaris Venture Management Co V LLC | 1.86% | 1,827,992 | $233.98k | Insider |
| Domain Partners VIII LP | 1.84% | 1,807,820 | $231.40k | Insider |
| Alta Partners VIII LP | 1.81% | 1,778,064 | $227.59k | Insider |
| Chp II LP | 1.79% | 1,758,158 | $225.04k | Insider |
| Paul Schimmel | 1.58% | 1,551,908 | $198.64k | Insider |
| John Mendlein | 0.63% | 615,382 | $78.77k | Insider |
| James E. Flynn | 0.52% | 511,528 | $65.48k | Insider |
ATYR vs Biotech Stocks
Atyr Pharma Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.